EU and US could reach trade deal this weekend - Reuters
Troy Wichterman, the Chief Financial Officer of Biolife Solutions Inc. (NASDAQ:BLFS), recently sold 4,151 shares of the company’s common stock. The transaction, completed on March 11, 2025, was conducted at a price of $25 per share, amounting to a total sale value of $103,775. The sale comes as the company, currently valued at $1.17 billion, trades near its 52-week high of $29.55, with InvestingPro analysis indicating the stock is slightly overvalued at current levels.
Following this transaction, Wichterman holds 116,809 shares of Biolife Solutions. According to the filing, the sale was made under a pre-established Rule 10b5-1 trading plan, which was set up to satisfy tax withholding obligations related to the vesting of restricted stock. The company maintains a strong financial position with a current ratio of 4.54 and operates with moderate debt levels. InvestingPro subscribers can access detailed insider trading patterns and 7 additional key insights about BLFS, along with comprehensive financial health metrics in the Pro Research Report.
In other recent news, BioLife Solutions reported fourth-quarter revenue of $22.7 million, surpassing analyst estimates, and a net loss of $2.0 million, which was smaller than anticipated. The company’s Cell Processing segment experienced significant growth, with revenue increasing 37% year-over-year to $20.3 million. BioLife has been successful in embedding its biopreservation media in 17 approved cell and gene therapies, with potential for further approvals in the next year. H.C. Wainwright raised its price target for BioLife Solutions to $30, maintaining a "Buy" rating, following these strong financial results. Benchmark also reiterated a Buy rating with a $30 target, highlighting the company’s performance and optimistic outlook for 2025. BioLife expects total revenue for 2025 to range between $95.5 million and $99.0 million, indicating a projected growth of 16-20%. The company has completed the sale of a non-core product line, aiming to improve gross and adjusted EBITDA margins. Management anticipates Cell Processing revenue to grow by 18-21% in 2025. These developments reflect BioLife’s strategic focus on its core business and its anticipated financial growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.